Drug Shortage Prevention Act of 2023
Latest action · May 5, 2023 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedApr 28, 2023
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Drug Shortage Prevention Act of 2023
This bill requires drug manufacturers to notify the Food and Drug Administration (FDA) if there is an increased demand for certain critical essential medicines that may result in a shortage.
Currently, drug manufacturers are required to notify the FDA in the event of a discontinuation or interruption in the supply of prescription drugs that are life-supporting, life-sustaining, or used for a debilitating disease or condition, including those used in medical emergencies, surgeries, or public health emergencies.
The bill requires drug manufacturers to also notify the FDA if there is an increased demand for such drugs that lasts for at least six weeks and that may result in a shortage. Manufacturers must initially notify the FDA of the increased demand within 48 hours after this six-week period and must submit an additional notice within 30 days of the initial notification. The notice must include the reasons for the increased demand, the expected duration, and any other information the FDA requires. The bill's requirements apply to both prescription and nonprescription drugs.
Cosponsors 49
Members who signed on, in the order they did. Signatures ran from Apr 28, 2023 to Jul 18, 2024; 29 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-CA | Adam B. Schiff | Original | Apr 28, 2023 |
| D-WA | Adam Smith | Original | Apr 28, 2023 |
| D-NY | Alexandria Ocasio-Cortez | Original | Apr 28, 2023 |
| D-NJ | Andy Kim | Original | Apr 28, 2023 |
| D-NH | Ann M. Kuster | Original | Apr 28, 2023 |
| D-MA | Ayanna Pressley | Original | Apr 28, 2023 |
| D-CA | Barbara Lee | Original | Apr 28, 2023 |
| D-NJ | Bonnie Watson Coleman | Original | Apr 28, 2023 |
| D-TX | Colin Z. Allred | Original | Apr 28, 2023 |
| R-FL | Cory Mills | Original | Apr 28, 2023 |
| D-DC | Eleanor Holmes Norton | Original | Apr 28, 2023 |
| D-MO | Emanuel Cleaver | Original | Apr 28, 2023 |
| D-MA | James P. McGovern | Original | Apr 28, 2023 |
| D-CA | Jared Huffman | Original | Apr 28, 2023 |
| D-TX | Jasmine Crockett | Original | Apr 28, 2023 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Apr 28, 2023 |
| Health Subcommittee | Referred May 5, 2023 |
Actions 3
Everything that happened, newest first.
- May 5, 2023Referred to the Subcommittee on Health.
- Apr 28, 2023Introduced in House
- Apr 28, 2023Referred to the House Committee on Energy and Commerce.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 169, no. 72, April 28, 2023, page H2119.
Printed hearings 1
Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.
| Number | Hearing | Committee | Held |
|---|---|---|---|
| S. Hrg. 118-709 | THE DEPARTMENT OF DEFENSE'S EFFORTS TO ENSURE SERVICEMEMBERS' ACCESS TO SAFE, HIGH-QUALITY PHARMACEUTICALS130 pages | Armed Services Committee | Apr 30, 2024 |
Related bills 1
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| HR 4697 | Protecting PAHPA Act of 2023 | Related bill | Jul 21, 2023 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To amend the Federal Food, Drug, and Cosmetic Act to provide for notification by manufacturers of critical essential medicines of increased demand of such drugs, and for other purposes.
- Short Title(s) as Introduced
- Drug Shortage Prevention Act of 2023
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- Apr 28, 2023Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.
